Real-World Analysis of Clinical and Demographic Characteristics, Treatment Patterns, and Outcomes in Predominantly Older Patients with HR+/HER2− Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice

Real-World Analysis of Clinical and Demographic Characteristics, Treatment Patterns, and Outcomes in Predominantly Older Patients with HR+/HER2− Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice

Abstract Introduction Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) is the most frequently diagnosed metastatic breast cancer (mBC) subtype. Combinations of endocrine therapy (ET) with cyclin-dependent kinase 4/6 inhibitors (CDK4 & 6is) improve outcome...

Full description

Bibliographic Details
Main Authors: Alistair Ring, Meghan Karuturi, Emily Nash Smyth, Tasneem Lokhandwala, Kristin M. Sheffield, Joanne Willey, Orsolya Lunacsek, Francisco Sapunar, Zhanglin Lin Cui, Anna D. Coutinho, Sarah Rybowski
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-09-01
Series:Drugs - Real World Outcomes
Online Access:https://doi.org/10.1007/s40801-023-00391-1

Internet

https://doi.org/10.1007/s40801-023-00391-1

Similar Items